Scientific-research deductions depend on applicable DSIR requirements, while alternate claims require independent examination and Rule 8D uses gross assets.
For A.Y. 2016-17, approved in-house R&D expenditure could not be limited to the amount quantified in DSIR Form 3CL because the applicable provisions required facility approval, not item-wise or quantum certification. The balance additional depreciation on eligible assets used for less than 180 days could be claimed in the succeeding year. Under Rule 8D, average total assets must use gross balance-sheet figures rather than written down fixed-asset values and net current assets. From 1 July 2016, DSIR quantification governs weighted deduction under section 35(2AB), while claims under other scientific-research provisions require separate examination.
Issues: (i) Whether, for A.Y. 2016-17, weighted deduction for expenditure on an approved in-house R&D facility could be restricted to the amount quantified by DSIR in Form 3CL; (ii) Whether the balance 50% of additional depreciation on eligible assets used for less than 180 days could be claimed in the immediately succeeding year; (iii) Whether, under Rule 8D, average total assets could be computed using written down value of fixed assets and net current assets; (iv) Whether, for A.Ys. 2017-18 and 2018-19, DSIR quantification in Form 3CL bound the tax authorities for weighted deduction, and whether unapproved expenditure could independently qualify under other scientific-research deduction provisions.
Issue (i): Whether, for A.Y. 2016-17, weighted deduction for expenditure on an approved in-house R&D facility could be restricted to the amount quantified by DSIR in Form 3CL.
Analysis: As applicable to A.Y. 2016-17, section 35(2AB) and Rule 6(7A) required approval of the in-house R&D facility, not DSIR certification of each item or quantum of expenditure. The facility held valid approval, and the genuineness and scientific-research nexus of the expenditure were not disputed. The subsequent requirement for DSIR quantification imposed an additional condition and operated prospectively.
Conclusion: For A.Y. 2016-17, the deduction could not be restricted merely to the amount stated in Form 3CL; the finding is in favour of the assessee.
Issue (ii): Whether the balance 50% of additional depreciation on eligible assets used for less than 180 days could be claimed in the immediately succeeding year.
Analysis: Section 32(1)(iia) conferred a one-time incentive, while the second proviso to section 32(1) restricted allowance in the acquisition year where use was below 180 days. That restriction did not extinguish the remaining entitlement. The third proviso applicable from A.Y. 2016-17 expressly allowed the balance in the succeeding year and was consistent with the beneficial object of additional depreciation.
Conclusion: The balance 50% additional depreciation was allowable in the immediately succeeding year; the finding is in favour of the assessee.
Issue (iii): Whether, under Rule 8D, average total assets could be computed using written down value of fixed assets and net current assets.
Analysis: Rule 8D(2)(ii) prescribes the average of total assets as appearing in the balance sheet. Its formula does not permit replacement of gross asset figures with written down values or reduction of current assets by current liabilities. Such substitutions reduce the denominator and impermissibly inflate the disallowance.
Conclusion: Average total assets must be taken from the gross balance-sheet figures, without the Assessing Officer's substitutions; the finding is in favour of the assessee.
Issue (iv): Whether, for A.Ys. 2017-18 and 2018-19, DSIR quantification in Form 3CL bound the tax authorities for weighted deduction, and whether unapproved expenditure could independently qualify under other scientific-research deduction provisions.
Analysis: Following the insertion of Rule 6(7A)(b) from 01.07.2016, DSIR was statutorily entrusted with quantifying expenditure eligible for weighted deduction under section 35(2AB). Tax authorities could not substitute their views for the technical determination of that expert authority. However, denial of DSIR approval for weighted deduction did not by itself determine eligibility under sections 35(1)(i), 35(1)(iv), and 35(2), whose conditions require independent examination.
Conclusion: The restriction of weighted deduction to DSIR-approved expenditure was sustained against the assessee, but the alternate claims under sections 35(1)(i), 35(1)(iv), and 35(2) were remitted for fresh determination; the finding is partly in favour of the assessee.
Final Conclusion: The Revenue's substantive challenges for A.Y. 2016-17 fail, while the assessee's claims for weighted deduction for A.Ys. 2017-18 and 2018-19 fail to that extent; independent eligibility of the alternate scientific-research claims remains to be determined afresh.